Rethinking RTSM Software: When Bigger Isn't Better

By Ryan Keane, founder and CEO, Korio

In clinical operations, the "safe" choice is often equated with the largest name. However, as the eClinical landscape undergoes rapid consolidation, many legacy providers are trading innovation for short-term financial goals. For small and mid-sized biopharma companies, this shift often manifests as a "service tax"—stagnant product roadmaps, high staff turnover, and a dilution of technical expertise as dedicated support is replaced by generalized management. When a vendor prioritizes margins over mastery, the resulting inertia doesn't just slow down progress; it introduces creeping fragility into randomization and supply chain integrity.

True risk mitigation in modern clinical trials requires moving away from the "bigger is better" fallacy. Instead of settling for a partner in maintenance mode, forward-thinking sponsors are seeking specialists who mirror their own agility. Navigating complex protocols and fluid timelines requires a team that views RTSM as a core discipline rather than a secondary checkbox. By prioritizing deep domain experience and a culture of proactive investment, sponsors can transform their clinical technology from a potential bottleneck into a reliable engine for trial success.